132 related articles for article (PubMed ID: 8888813)
1. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
[TBL] [Abstract][Full Text] [Related]
2. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma.
Valteau-Couanet D; Rubie H; Meresse V; Farace F; Brandely M; Hartmann O
Bone Marrow Transplant; 1995 Oct; 16(4):515-20. PubMed ID: 8528166
[TBL] [Abstract][Full Text] [Related]
4. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
6. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients.
Messina C; Zambello R; Rossetti F; Gazzola MV; Varotto S; Destro R; Basso G; Semenzato G; Zanesco L
Bone Marrow Transplant; 1996 May; 17(5):729-35. PubMed ID: 8733689
[TBL] [Abstract][Full Text] [Related]
8. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
9. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
[TBL] [Abstract][Full Text] [Related]
10. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
11. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
12. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
Favrot MC; Floret D; Negrier S; Cochat P; Bouffet E; Zhou DC; Franks CR; Bijman T; Brunat-Mentigny M; Philip I
Bone Marrow Transplant; 1989 Sep; 4(5):499-503. PubMed ID: 2790327
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Higuchi CM; Thompson JA; Petersen FB; Buckner CD; Fefer A
Blood; 1991 Jun; 77(12):2561-8. PubMed ID: 2043762
[TBL] [Abstract][Full Text] [Related]
14. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.
Blaise D; Viens P; Olive D; Stoppa AM; Gabert J; Pourreau CN; Attal M; Gaspard MH; Mannoni P; Jasmin C
Eur Cytokine Netw; 1991; 2(2):121-9. PubMed ID: 1813015
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of stage IV neuroblastoma with high-dose melphalan and autologous bone marrow transplantation following in vitro preliminary treatment of the bone marrow with the active cyclophosphamide derivative Asta Z-7654].
Urban C; Slace I; Kaulfersch W; Greinix H; Höcker P
Padiatr Padol; 1986; 21(3):275-82. PubMed ID: 3534689
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
López-Jiménez J; Pérez-Oteyza J; Munoz A; Parra C; Villalón L; Ramos P; Maldonado M; García-Laraña J; Otheo E; Roldán E; García-Avello A; Odriozola J
Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
[TBL] [Abstract][Full Text] [Related]
18. [Adoptive immunotherapy with interleukin 2 in oncology].
Favrot M; Bouffet E; Négrier S; Combaret V; Philip I; Philip T
Bull Cancer; 1990; 77(9):925-31. PubMed ID: 2224165
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.
Meehan KR; Verma UN; Cahill R; Frankel S; Areman EM; Sacher RA; Foelber R; Rajagopal C; Gehan EA; Lippman ME; Mazumder A
Bone Marrow Transplant; 1997 Oct; 20(8):643-51. PubMed ID: 9383227
[TBL] [Abstract][Full Text] [Related]
20. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
Tiberghien P; Racadot E; Fest T; Lioure B; Pariset J; Delain M; Voillat L; Flesch M; Amsallem D; Plouvier E
Bone Marrow Transplant; 1991; 7 Suppl 2():145. PubMed ID: 1878686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
